However, the promising efficacy and safety profile of [177Lu]Lu-PSMA-617 in previously treated patients has generated interest in exploring treatment combinations and the early use of [177Lu]Lu-PSMA-617 in the PCa natural history. Here, FOLH1 is linked to posterior cortical atrophy.